enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Salbutamol - Wikipedia

   en.wikipedia.org/wiki/Salbutamol

   Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, [1] is a medication that opens up the medium and large airways in the lungs. [8] It is a short-acting β 2 adrenergic receptor agonist that causes relaxation of airway smooth muscle. [8]

3. Salbutamol/budesonide - Wikipedia

   en.wikipedia.org/wiki/Salbutamol/budesonide

   Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. [1] [2] It is a combination of salbutamol sulfate (albuterol sulfate), a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid.

4. Inhaler - Wikipedia

   en.wikipedia.org/wiki/Inhaler

   An inhaler (puffer, asthma pump or allergy spray) is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications.

5. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   An investigation by the Democratic-led Senate Committee on Health, Education, Labor and Pensions noted AstraZeneca charges $645 in the U.S. for the same inhaler it charges $49 for in the U.K. Teva ...

6. Bronchodilator - Wikipedia

   en.wikipedia.org/wiki/Bronchodilator

   These are quick-relief or "rescue" medications that provide quick, temporary relief from asthma symptoms or flare-ups. These medications usually take effect within 20 minutes or less, and can last from four to six hours. These inhaled medications are best for treating sudden and severe or new asthma symptoms.

7. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

   www.aol.com/news/astrazeneca-cap-us-pocket-costs...

   (Reuters) -AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, starting June, following a similar move by rival ...